Celgene (NASDAQ:CELG)

Test tubes

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the May 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Money and plant

4 Large Cap Growth Stocks to Buy With Incredible 10-Year Track Records

If there is one thing that investors look for in growth stocks it is consistency. Companies that can continue to put out solid metrics over long periods make good additions ...
Read Full Story »
Test tubes

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Test tubes

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

All sectors of the market tend to have times of the year that are better than others, and biotechnology is no different. Typically each year, the first quarter is the ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Test tubes

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

The flurry of earnings starts this week, and depending on who you listen to, the numbers are either going to be fine or they will be disappointing. One thing is ...
Read Full Story »
graph

3 Hot Growth Stocks With Upside Potential That May Not Be Appreciated by Wall Street

Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially if they made a good call on the stock and ...
Read Full Story »
graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
analysis

The Next Mega-Caps: 7 Stocks Likely to Be Worth $100 Billion Soon

Now that stocks have charged back from the depths of the January and February selling, the Dow Jones Industrial Average (DJIA) and S&P 500 managed to come back to positive ...
Read Full Story »
biotech word cloud

Short Sellers Back Off of Major Biotechs

The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
graph

3 Top Biopharma Movers of the Past Week

Over the past week, a few biotech companies made impressive runs. These moves were the result of positive trial results and a U.S. Food and Drug Administration (FDA) meeting. The ...
Read Full Story »
biotech word cloud

Why Citi Sees Huge Upside in 4 Top Biotechs Now

If there was one sector inside of a broader health care theme that performed well through much of 2015, it was biotech. That was then, and this is now. A ...
Read Full Story »
graph

Short Interest Rises Across the Board in Major Biotechs

The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »